| |
Ctl (n = 9)
|
CCh (n = 9)
|
CCh + pir (n = 9)
|
|---|
|
Field max (mV)
|
−0.75 ± 0.25
|
−0.29 ± 0.16 (*)
|
−0.69 ± 0.24 (+)
|
|
EPSP max (mV)
|
24.3 ± 1.5
|
20.6 ± 2 (*)
|
23.6 ± 1.7 (+)
|
|
I
50
(V)
|
5.12 ± 0.81
|
9.23 ± 1.71 (*)
|
6.22 ± 0.94 (*) (+)
|
|
Slope factor
|
1.61 ± 0.59
|
4.16 ± 0.95 (*)
|
1.52 ± 0.40 (+)
|
| |
Ctl (n = 7)
|
pir (n = 7)
|
pir + CCh (n = 7)
|
|
Field max (mV)
|
−0.68 ± 0.3
|
−0.7 ± 0.29
|
−0.56 ± 0.25 (+)
|
|
EPSP max (mV)
|
20.5 ± 5.3
|
20.3 ± 5.1
|
16.0 ± 4 (*) (+)
|
|
I
50
(V)
|
8.41 ± 0.75
|
8.45 ± 0.76
|
9.37 ± 1.04 (*)
|
|
Slope factor
|
1.93 ± 0.54
|
2.18 ± 0.68
|
1.95 ± 0.31
|
- The order of two drugs given in the figures indicates the sequence of application (i.e. “CCh + pir” means pirenzepine was added to a CCh containing ACSF and vice versa)
- These experiments were performed in STRC
- *: p < 0.05 vs. control, +: p < 0.05 vs. previous condition
